TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03015636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusted CBT-i for ADHD
Description: This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
Study: NCT03353025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dopamine agonist treatment
Description: Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
Study: NCT04065997

Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Study: NCT03015636

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
Study: NCT04708093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: Oscillating platform
Study: NCT01214005

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smoking abstinence
Description: 3 days of biologically-confirmed smoking abstinence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking abstinence
Description: 3 days of biologically-confirmed smoking abstinence
Study: NCT04394065

Intervention type: DEVICE
Intervention: ultrasensitive positron emission tomography
Description: A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)
Study: NCT02552134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: recommendation to be active
Study: NCT03797846

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined glaucoma surgery
Description: combined procedure with trabeculectomy and cataract removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined glaucoma surgery
Description: combined procedure with trabeculectomy and cataract removal
Study: NCT01113125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethason-17-valerate and fusidic acid
Description: 0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
Study: NCT03309423

Intervention type: DIAGNOSTIC_TEST
Intervention: venous to arterial conversion (v-TAC)
Description: Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.

Intervention type: DIAGNOSTIC_TEST
Intervention: venous to arterial conversion (v-TAC)
Description: Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.

Intervention type: DIAGNOSTIC_TEST
Intervention: venous to arterial conversion (v-TAC)
Description: Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
Study: NCT02976935

Intervention type: OTHER
Intervention: hyperpolarised 129 Xenon
Description: Hyperpolarised 129 Xe to assess lung function

Intervention type: OTHER
Intervention: hyperpolarised 129 Xenon
Description: Hyperpolarised 129 Xe to assess lung function
Study: NCT00746616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durom Hip Resurfacing System
Description: Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
Study: NCT02151188

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bread, Soy milk and cow milk
Description: The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread, Soy milk and cow milk
Description: The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread, Soy milk and cow milk
Description: The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread, Soy milk and cow milk
Description: The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread, Soy milk and cow milk
Description: The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.

Intervention type: DEVICE
Group type: OTHER
Intervention: real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)
Study: NCT00296777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 8 weeks: up to 40 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: 8 weeks: up to 300mg/day~\*if patient does not have contraindication.
Study: NCT01113125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fusidic Acid
Description: 0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
Study: NCT02151188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)
Study: NCT03106701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Epicardial Radiofrequency ablation
Study: NCT01710007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1PC002
Description: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Study: NCT02151188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)
Study: NCT03976388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Virtual Simulator
Description: Interactive medical case delivered using touch-sensitive screens in small group sessions.
Study: NCT01710007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor
Description: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Study: NCT03938454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizanlizumab
Description: Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
Study: NCT03976388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small-Group Discussion
Description: Small group discussion led by a physician.
Study: NCT01100320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 40-mg tablet x 1 dose taken with food
Study: NCT03890380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magneto Wire
Description: Patients will be treated with Magneto Wire
Study: NCT01100320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
Study: NCT03561272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Phone Application
Description: Oral medication adherence phone application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smart Phone Application
Description: Oral medication adherence phone application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POD
Description: Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
Study: NCT05429749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
Study: NCT01627613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP301
Description: AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
Study: NCT05429749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline 250ml is administered between the admission day and the surgery day.
Study: NCT04005261

Intervention type: DIAGNOSTIC_TEST
Intervention: C-peptide concentrations
Description: The patients will be grouped by their C-peptide concentrations
Study: NCT00500188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: 300 mg orally twice daily
Study: NCT03215602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEMEX and education + strength training
Description: Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NEMEX and education
Description: Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
Study: NCT01798056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK 1437173A
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
Study: NCT04591327

Intervention type: PROCEDURE
Intervention: The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections
Description: Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is\> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.

Intervention type: PROCEDURE
Intervention: The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections
Description: Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is\> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
Study: NCT02510131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises
Description: To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
Study: NCT02049931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No brace treatment
Description: Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid brace
Description: In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft brace
Description: In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
Study: NCT04544358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAILAMOS©
Description: BAILAMOS© includes a 4-month, twice-weekly dance program. The PI and a professional dance instructor co-developed an extensive BAILAMOS© Dance Manual and class-by-class schedule.
Study: NCT01951651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide
Description: Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
Study: NCT03233113

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure therapy
Description: Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Description: Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, \& Whiteside, 20011; Antony, Craske, \& Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, \& Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider.
Study: NCT03198819

Intervention type: DRUG
Intervention: Local Rifampisin and İnrtravenous cefotaxime
Study: NCT01708317

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACASI
Description: Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
Study: NCT02407483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Visual Guidance
Description: Laparoscopic simulator training, tested with laser visual guidance
Study: NCT00596960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
Study: NCT03204318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1.0 mg)/NETA (0.5 mg) administered orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/norethindrone acetate placebo
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor.
Study: NCT02407483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 D vision
Description: Laparoscopic simulator training, tested without laser visual guidance
Study: NCT03418025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo Exercise Together intervention
Study: NCT02583581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring (MindWave by NeuroSky)
Description: EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG monitoring (EPOC by Emotiv)
Description: EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
Study: NCT03029624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCoin
Description: Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.